Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Arsenic trioxide
Drug ID BADD_D00169
Description Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Indications and Usage For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
Marketing Status approved; investigational
ATC Code L01XX27
DrugBank ID DB01169
KEGG ID D02106
MeSH ID D000077237
PubChem ID 14888
TTD Drug ID D07VIK
NDC Product Code 64743-400; 14789-600; 49315-007; 54973-0605; 68428-033; 70710-1610; 43406-0168; 49315-005; 68083-462; 68428-225; 64757-0001; 23155-870; 0220-0522; 0220-0527; 0220-0549; 70710-1896; 55150-366; 25021-226; 43406-0318; 0220-0554; 0220-0557; 63323-637; 81607-005; 64757-0016; 0220-0528; 54879-027; 62106-4878; 58621-001; 0220-0530; 68428-083; 70710-1895; 0220-0553; 63459-601; 69918-720; 70121-1483; 76472-3004; 81607-006; 72659-245; 0220-0526; 50742-438; 68083-535; 0781-3498; 54875-0005; 23155-869; 25021-227; 0220-0525; 0220-0550; 68382-997; 70121-1658; 70860-217; 76472-1132; 76472-4004; 0220-0529
UNII S7V92P67HO
Synonyms Arsenic Trioxide | As2O3 | Arsenous Anhydride | Diarsenic Trioxide | Arsenic Oxide (As2O3) | Arsenic(III) Oxide | Tetraarsenic Oxide | Arsenolite | As4O6 | Tetra-Arsenic Oxide | Tetra Arsenic Oxide | Tetraarsenic Hexaoxide | Arsenic Oxide (As4O6) | Tetra-Arsenic Hexaoxide | Tetra Arsenic Hexaoxide | Naonobin | Trisenox | Trixenox
Chemical Information
Molecular Formula As2O3
CAS Registry Number 1327-53-3
SMILES [O-2].[O-2].[O-2].[As+3].[As+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular tachycardia02.03.04.0100.000168%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.0030.000414%
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000381%
Tubulointerstitial nephritis20.05.02.0020.000112%Not Available
Bradyarrhythmia02.03.02.0150.000280%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling08.02.03.017; 12.07.03.018--Not Available
Haemorrhage24.07.01.0020.000168%Not Available
Angiopathy24.03.02.007--Not Available
Drug resistance08.06.01.0050.000168%Not Available
Cardiac disorder02.11.01.003--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Blood disorder01.05.01.004--Not Available
Renal impairment20.01.03.0100.000246%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.000112%
Breath sounds abnormal13.15.01.008--Not Available
Oropharyngeal blistering22.12.03.014; 07.05.05.006--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Acute kidney injury20.01.03.0160.000336%
Upper-airway cough syndrome22.12.03.036--
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000112%Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene